갈렉토(GLTO)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $22.78 (-7.13%), 시가총액 $1.73B, 52주 최저~최고 $2.58 ~ $34.14.
Damora Therapeutics, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases. It develops GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 and GB1211, an oral small molecule inhibitor of galectin-3 to treat multiple types of oncology and liver disease indications. The company was founded in 2011 and is headquartered in Copenhagen, Denmark.
갈렉토의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
갈렉토의 현재 주가는 $22.78 (-7.13%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
갈렉토의 시가총액은 약 $1.73B입니다.
Damora Therapeutics, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases. It develops GB3226, a